Skip to main content
. 2019 Nov 12;11(11):1780. doi: 10.3390/cancers11111780

Table 1.

Patient demographics and clinical characteristics.

Variable All Patients
N = 479
No. (%)
Primary AS
N = 169
No. (%)
Secondary AS
N = 259
No. (%)
Unknown AS
N = 51
No. (%)
p-value
Age <0.011,2
Median age (range) 70 (2–98) 66 (2–96) 74 (38–98) 62 (15–83)
Gender <0.01
Male 167 (34.9) 74 (43.8) 62 (23.9) 31 (61.8)
Female 312 (65.1) 95 (56.2) 197 (76.1) 20 (39.2)
Time since radiation therapy
Median time (years, range) 8 (1–19) - 8 (1–19) - -
Tumor size 0.601
≤ 5 cm 43 (9.0) 14 (8.3) 25 (9.7) 4 (7.8)
> 5 cm 26 (5.4) 7 (4.1) 14 (5.4) 5 (9.8)
Unknown 410 (85.6) 148 (87.6) 220 (84.9) 42 (82.4)
Tumor depth <0.01
Superficial 134 (28.0) 21 (12.4) 112 (43.2) 1 (2.0)
Deep 25 (5.2) 16 (9.5) 3 (1.2) 6 (11.8)
Unknown 320 (66.8) 132 (78.1) 144 (55.6) 44 (86.3)
Distant metastasis <0.01
No 324 (67.6) 106 (62.7) 201 (77.6) 17 (33.3)
Yes 79 (16.5) 37 (21.9) 19 (7.3) 23 (45.1)
Unknown 76 (15.9) 26 (15.4) 39 (15.1) 11 (21.6)
Surgery <0.01
Yes 306 (63.9) 107 (63.3) 192 (74.1) 7 (13.7)
No 173 (36.1) 62 (36.7) 67 (25.9) 44 (86.3)
Residual disease 0.273
R0 12 (2.5) 4 (3.7) 7 (3.6) 1 (14.3)
R1 4 (0.8) 0 (0.0) 4 (2.1) 0 (0.0)
Unknown 463 (96.7) 103 (96.3) 181 (94.3) 6 (85.7)
Radiation therapy 0.217
Neoadjuvant 3 (0.6) 0 (0.0) 2 (0.8) 1 (2.0)
Adjuvant 49 (10.2) 20 (11.8) 27 (10.4) 2 (3.9)
Neoadjuvant + adjuvant 2 (0.4) 0 (0.0) 2 (0.8) 0 (0.0)
Primary 41 (8.6) 9 (5.3) 26 (10.0) 6 (11.8)
No 384 (80.2) 140 (82.8) 202 (78.0) 42 (82.4)
Chemotherapy <0.01
Neoadjuvant 5 (1.0) 2 (1.2) 3 (1.2) 0 (0.0)
Adjuvant 7 (1.5) 6 (3.6) 1 (0.4) 0 (0.0)
Primary 47 (9.8) 13 (7.7) 22 (8.5) 12 (23.5)
No 420 (87.7) 148 (87.6) 233 (90.0) 39 (76.5)

1 primary vs secondary AS, 2 unknown vs secondary AS.